Skip to main content
. Author manuscript; available in PMC: 2011 Jun 8.
Published in final edited form as: Circulation. 2010 May 17;121(22):2462–2508. doi: 10.1161/CIR.0b013e3181d44a8f

Appendix 2.

Peer Reviewer Relationships With Industry and Other Entities—ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance

Peer Reviewer Representation Consultant Speaker Ownership/Partnership/Principal Research Institutional, Organizational, or Other Financial Benefit Expert Witness
Dr. James C. Carr Official Reviewer—North American Society for Cardiovascular Imaging None None None None None None
Dr. Michael G. Del Core Official Reviewer—ACCF Board of Governors None None None None None None
Dr. Andre Duerinckx Official Reviewer—American College of Radiology None None None • Philips Medical Systems
• Schering-Plough
None None
Dr. Mark J. Eisenberg Official Reviewer—ACCF Task Force on Clinical Expert Consensus Documents None None None None None None
Dr. Victor A. Ferrari Official Reviewer—Society for Cardiovascular Magnetic Resonance Imaging None None None None None None
Dr. Gautham Reddy Official Reviewer—American College of Radiology None None None None None None
Dr. Orlando Simonetti Official Reviewer—North American Society for Cardiovascular Imaging None None • Siemens Healthcare None None None
Dr. James E. Udelson Official Reviewer—ACCF Board of Trustees; American Heart Association None None None None None None
Dr. Sanjay Kaul Content Reviewer—ACCF Task Force on Clinical Expert Consensus Documents None None None None None None
Dr. Debabrata Mukherjee Content Reviewer—ACCF Task Force on Clinical Expert Consensus Documents None None None None None None
Dr. Robert S. Rosenson Content Reviewer—ACCF Task Force on Clinical Expert Consensus Documents • Abbott
• Anthera
• AstraZeneca*
• Daiichi Sankyo
• LipoScience*
• Roche
None • LipoScience* None • Grain Board None
Dr. Jonathan W. Weinsaft Content Reviewer—*Individual None None None • Lantheus Medical Imaging None None

This table represents the relevant relationships with industry and other entities that were disclosed by reviewers at the time of peer review. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10 000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Participation in the peer review process does not imply endorsement of this document.

*

Significant (greater than $10 000) relationship.